A new patent licencing deal between Cornell and LNC Therapeutics will help the French biotech become the ‘must have’ partner for research and product development relating to the Christensenella strain, says the company’s CEO.
Clic here to read the full article
In the same category
Seventure Partners : Une croissance continue dans le secteur du microbiome en 2021 qui va se...
Mar 15, 2022
more +